Atlas Venture Fund X, L.P.'s Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Nov 4, 2022
- Accession no.
- 0001209191-22-055808
- Filed
- Nov 4, 2022, 4:30 PM ET
- Trade date
- Nov 2-3, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $6.60M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund X, L.P.CIK 0001628098 | 10% Owner |
| Atlas Venture Associates X, LLCCIK 0001742765 | 10% Owner |
| Atlas Venture Associates X, L.P.CIK 0001742766 | 10% Owner |
| Atlas Venture Opportunity Fund I, L.P.CIK 0001759241 | 10% Owner |
| Atlas Venture Associates Opportunity I, L.P.CIK 0001780065 | 10% Owner |
| Atlas Venture Associates Opportunity I, LLCCIK 0001780066 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2022 | Common Stock | SSaleDisposed | −96,581 | $30.02F2 | −$2,899,361.62 | 5,440,875 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −27,038 | $30.02F2 | −$811,680.76 | 1,022,502 | Indirect | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −75,312 | $30.00F5 | −$2,259,360 | 5,365,563 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −21,085 | $30.00F5 | −$632,550 | 1,001,417 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.61 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.